Mesenchymal stem cells for the treatment of systemic lupus erythematosus: Is the cure for connective tissue diseases within connective tissue?

Stem Cell Research and Therapy

Volumn 2, Issue 3, 2011, Pages

  Carrion, Flavio A ^a   Figueroa, Fernando E ^a  

^a UNIVERSIDAD DE LOS ANDES   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; SIGNAL PEPTIDE;

ADULT STEM CELL; ALLOGENEIC MESENCHYMAL STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; AUTOLOGOUS MESENCHYMAL STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL HOMING; DRUG DOSE REDUCTION; DRUG RESPONSE; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPOTENT STEM CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; TH2 CELL; THERAPY EFFECT; ADULT; ALLOTRANSPLANTATION; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE DISEASES; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MOUSE; NEW ZEALAND BLACK MOUSE; TREATMENT OUTCOME; XENOGRAFT;

ADULT; ANIMALS; CLINICAL TRIALS AS TOPIC; CONNECTIVE TISSUE DISEASES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, INBRED NZB; MODELS, BIOLOGICAL; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 80052402855     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt64     Document Type: Review

References (73)

1. Trends in deaths from systemic lupus erythematosus US 1979-1998. Sacks JJ, Helmick CG, Langmaid G, Sniezek JE, MMWR Morb Mortal Wkly Rep 2002 51 371 374 12018384
2. Mortality in systemic lupus erythematosus. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcán G, Senécal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, et al. Arthritis Rheum 2006 54 2550 2557 10.1002/art.21955 16868977 (Pubitemid 44205016)
3. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Nossent J, Kiss E, Rozman B, Pokorny G, Vlachoyiannopoulos P, Olesinska M, Marchesoni A, Mosca M, Påi S, Manger K, Schneider M, Nielsen H, van Vollenhoven R, Swaak T, Lupus 2010 19 949 956 10.1177/0961203310366572 20375124
4. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT, Ann Intern Med 2001 135 248 257 11511139 (Pubitemid 32799338)
5. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D, Aspreva Lupus Management Study Group, J Am Soc Nephrol 2009 20 1103 1112 10.1681/ASN.2008101028 19369404
6. Osteogenesis in transplants of bone marrow cells. Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV, J Embryol Exp Morphol 1966 16 381 390 5336210
7. Multilineage potential of adult human mesenchymal stem cells. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR, Science 1999 284 143 147 10.1126/science.284.5411.143 10102814 (Pubitemid 29282067)
8. Simplification of aggregate culture of human mesenchymal stem cells as a chondrogenic screening assay. Welter JF, Solchaga LA, Penick KJ, Biotechniques 2007 42 732 737 10.2144/000112451 17612296 (Pubitemid 47035980)
9. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R, Exp Hematol 2002 30 42 48 10.1016/S0301-472X(01)00769-X 11823036 (Pubitemid 34059216)
10. Immunoregulatory function of mesenchymal stem cells. Uccelli A, Moretta L, Pistoia V, Eur J Immunol 2006 36 2566 2573 10.1002/eji.200636416 17013987 (Pubitemid 44608440)
11. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Tyndall A, Walker UA, Cope A, Dazzi F, De Bari C, Fibbe W, Guiducci S, Jones S, Jorgensen C, Le Blanc K, Luyten F, McGonagle D, Martin I, Bocelli-Tyndall C, Pennesi G, Pistoia V, Pitzalis C, Uccelli A, Wulffraat N, Feldmann M, Arthritis Res Ther 2007 9 301 10.1186/ar2103 17284303 (Pubitemid 47249052)
12. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Chamberlain G, Fox J, Ashton B, Middleton J, Stem Cells 2007 25 2739 2749 10.1634/stemcells.2007- 0197 17656645 (Pubitemid 350127858)
13. Immunomodulatory properties of mesenchymal stromal cells. Nauta AJ, Fibbe WE, Blood 2007 110 3499 3506 10.1182/blood-2007-02-069716 17664353 (Pubitemid 350159613)
14. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Nol D, Stem Cell Res Ther 2010 1 2 10.1186/scrt2 20504283
15. Bone marrow stem cell derived paracrine factors for regenerative medicine: current perspectives and therapeutic potential. Burdon T, Paul A, Noiseux N, Prakash S, Shum-Tim D, Bone Marrow Res 2011
16. miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Tome M, Lápez-Romero P, Albo C, Sepúlveda JC, Fernández-Gutiérrez B, Dopazo A, Bernad A, González MA, Cell Death Differ 2011 18 985 995 10.1038/cdd.2010.167 21164520
17. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E, Yuan S, Young YK, Boivin MN, Forner K, Basik M, Galipeau J, J Immunol 2009 182 5994 6002 10.4049/jimmunol.0803962 19414750
18. Human bone marrow derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, Miller RH, Glia 2009 57 1192 1203 10.1002/glia.20841 19191336
19. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/SCID mice. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, Prockop DJ, Proc Natl Acad Sci USA 2006 103 17438 17443 10.1073/pnas.0608249103 17088535 (Pubitemid 44788987)
20. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G, Arthritis Rheum 2007 56 1175 1186 10.1002/art.22511 17393437 (Pubitemid 46608642)
21. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M, Arthritis Rheum 2009 60 1006 1019 10.1002/art.24405 19333946
22. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Zhou K, Zhang H, Jin O, Feng X, Yao G, Hou Y, Sun L, Cell Mol Immunol 2008 5 417 424 10.1038/cmi.2008.52 19118507
23. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S, Stem Cells 2009 27 1421 1432 10.1002/stem.68 19489103
24. Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice. Gu Z, Akiyama K, Ma X, Zhang H, Feng X, Yao G, Hou Y, Lu L, Gilkeson GS, Silver RM, Zeng X, Shi S, Sun L, Lupus 2010 19 1502 1514 10.1177/0961203310373782 20647254
25. Immunomodulatory properties of stem cells from human exfoliated deciduous teeth. Yamaza T, Kentaro A, Chen C, Liu Y, Shi Y, Gronthos S, Wang S, Shi S, Stem Cell Res Ther 2010 1 5 10.1186/scrt5 20504286
26. Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease. Youd M, Blickarz C, Woodworth L, Touzjian T, Edling A, Tedstone J, Ruzek M, Tubo R, Kaplan J, Lodie T, Clin Exp Immunol 2010 161 176 186 20456409
27. Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis. Chang JW, Hung SP, Wu HH, Wu WM, Yang AH, Tsai HL, Yang LY, Lee OK, Cell Transplant 2011 20 245 257 10.3727/096368910X520056 20719085
28. Interferon - dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Schena F, Gambini C, Gregorio A, Mosconi M, Reverberi D, Gattorno M, Casazza S, Uccelli A, Moretta L, Martini A, Traggiai E, Arthritis Rheum 2010 62 2776 2786 10.1002/art.27560 20496367
29. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Schurgers E, Kelchtermans H, Mitera T, Geboes L, Matthys P, Arthritis Res Ther 2010 12 31 10.1186/ar2939 20175883
30. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/results?term=msc
31. Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1. Block GJ, Ohkouchi S, Fung F, Frenkel J, Gregory C, Pochampally R, DiMattia G, Sullivan DE, Prockop DJ, Stem Cells 2009 27 670 681 19267325
32. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. Chen L, Tredget EE, Wu PY, Wu Y, PLoS One 2008 3 1886 10.1371/journal.pone.0001886 18382669 (Pubitemid 351943822)
33. Mesenchymal stromal cells: facilitators of successful transplantation? English K, French A, Wood KJ, Cell Stem Cell 2010 7 431 442 10.1016/j.stem.2010. 09.009 20887949
34. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O, Lancet 2004 363 1439 1441 10.1016/S0140-6736(04)16104-7 15121408 (Pubitemid 38586721)
35. Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GVHD Trials. http://investor.osiris.com/releasedetail.cfm?releaseID=407404
36. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, Hua B, Liu B, Ye S, Hu X, Xu W, Zeng X, Hou Y, Gilkeson GS, Silver RM, Lu L, Shi S, Arthritis Rheum 2010 62 2467 2475 10.1002/art.27548 20506343
37. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y, Zeng X, Gilkeson GS, Sun L, Ann Rheum Dis 2010 69 1423 1429 10.1136/ard.2009.123463 20650877
38. Mesenchymal stem cells: a new therapeutic tool for AKI. Tögel FE, Westenfelder C, Nat Rev Nephrol 2010 6 179 183 10.1038/nrneph.2009.229 20186233
39. Repeated administration of bone marrow-derived mesenchymal stem cells improved the protective effects on a remnant kidney model. Lee SR, Lee SH, Moon JY, Park JY, Lee D, Lim SJ, Jeong KH, Park JK, Lee TW, Ihm CG, Ren Fail 2010 32 840 848 10.3109/0886022X.2010.494803 20662698
40. Mesenchymal stem cells: mechanisms of inflammation. Singer NG, Caplan AI, Annu Rev Pathol 2011 6 457 478 10.1146/annurev-pathol-011110-130230 21073342
41. The concept of connective tissue diseases. Klemperer P, Circulation 1962 25 869 871 14456866
42. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, Pistoia V, Martin I, Tyndall A, Rheumatology (Oxford) 2007 46 403 408 10.1093/rheumatology/kel267 (Pubitemid 46344649)
43. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM, Lupus 2007 16 121 128 10.1177/0961203306075793 17402368 (Pubitemid 46347934)
44. Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Nie Y, Lau C, Lie A, Chan G, Mok M, Lupus 2010 19 850 859 10.1177/0961203309361482 20511276
45. Autoimmune disease: is it a disorder of the microenvironment? El-Badri NS, Hakki A, Ferrari A, Shamekh R, Good RA, Immunol Res 2008 41 79 86 10.1007/s12026-007-0053-8 18506645 (Pubitemid 351903814)
46. T-regulatory cells in systemic lupus erythematosus. La Cava A, Lupus 2008 17 421 425 10.1177/0961203308090028 18490420 (Pubitemid 351798720)
47. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. Valencia X, Yarboro C, Illei G, Lipsky PE, J Immunol 2007 178 2579 2588 17277168 (Pubitemid 46233461)
48. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, Xu ZS, Lu YX, Liu D, Chen ZZ, Han ZC, Haematologica 2006 91 1017 1026 16870554
49. Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE. Liang J, Gu F, Wang H, Hua B, Hou Y, Shi S, Lu L, Sun L, Nat Rev Rheumatol 2010 6 486 489 10.1038/nrrheum.2010.80 20517294
50. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. Jones S, Horwood N, Cope A, Dazzi F, J Immunol 2007 179 2824 2831 17709496
51. Human mesenchymal stem cells modulate allogeneic immune cell responses. Aggarwal S, Pittenger MF, Blood 2005 105 1815 1822 10.1182/blood-2004-04-1559 15494428 (Pubitemid 40223708)
52. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Ryan JM, Barry F, Murphy JM, Mahon BP, Clin Exp Immunol 2007 149 353 363 10.1111/j.1365-2249.2007.03422.x 17521318 (Pubitemid 47063057)
53. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F, Romagnani P, Maggi E, Romagnani S, Annunziato F, Stem Cells 2006 24 386 398 10.1634/stemcells.2005-0008 16123384 (Pubitemid 44464808)
54. Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y, Cell Stem Cell 2008 2 141 150 10.1016/j.stem.2007. 11.014 18371435 (Pubitemid 351181031)
55. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, Genrich K, Mehrotra S, Setty S, Smith B, Bartholomew A, Eur J Immunol 2008 38 1745 1755 10.1002/eji.200738129 18493986
56. Interleukin-17-producing T cells in lupus. Crispin JC, Tsokos GC, Curr Opin Rheumatol 2010 22 499 503 10.1097/BOR.0b013e32833c62b0 20592603
57. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A, Haematologica 2007 92 881 888 10.3324/haematol.11240 17606437 (Pubitemid 350144234)
58. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Gonzalez-Rey E, Gonzalez MA, Varela N, O'Valle F, Hernandez-Cortes P, Rico L, Buscher D, Delgado M, Ann Rheum Dis 2010 69 241 248 10.1136/ard.2008.101881 19124525
59. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Carrion F, Nova E, Ruiz C, Diaz F, Inostroza C, Rojo D, Mönckeberg G, Figueroa FE, Lupus 2010 19 317 322 10.1177/0961203309348983 19919974
60. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R, Blood 2003 101 2999 3001 10.1182/blood-2002-06-1830 12480709 (Pubitemid 36857986)
61. Mesenchymal stem cells in acute kidney injury. Humphreys BD, Bonventre JV, Annu Rev Med 2008 59 311 325 10.1146/annurev.med.59.061506.154239 17914926 (Pubitemid 351287940)
62. The role of mesenchymal stem cells in the functional improvement of chronic renal failure. Choi S, Park M, Kim J, Hwang S, Park S, Lee Y, Stem Cells Dev 2009 18 521 529 10.1089/scd.2008.0097 18647091
63. Stromal cells protect against acute tubular injury via an endocrine effect. Bi B, Schmitt R, Israilova M, Nishio H, Cantley LG, J Am Soc Nephrol 2007 18 2486 2496 10.1681/ASN.2007020140 17656474 (Pubitemid 47378865)
64. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ, Cell Stem Cell 2009 5 54 63 10.1016/j.stem.2009.05. 003 19570514
65. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Robak E, Woniacka A, Sysa-Jedrzejowska A, Stepie H, Robak T, Eur Cytokine Netw 2001 12 445 452 11566625 (Pubitemid 32905263)
66. Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Navarro C, Candia-Zú̃iga L, Silveira LH, Ruiz V, Gaxiola M, Avila MC, Amigo MC, Lupus 2002 11 21 24 10.1191/0961203302lu131oa 11898914 (Pubitemid 34178115)
67. Mesenchymal stem cells treatment induces functional and morphological improvement in chronic renal failure model in rats. Villanueva S, Ewertz E, Carrián F, Tapia A, Vergara V, Céspedes C, Saez P, Luz P, Irarrázabal C, Carrẽo JE, Figueroa F, Vio C, Clin Sci 2011
68. Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus. Dai R, Zhang Y, Khan D, Heid B, Caudell D, Crasta O, Ahmed SA, PLoS One 2010 5 14302 10.1371/journal.pone. 0014302 21170274
69. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Chen TS, Lai RC, Lee MM, Choo AB, Lee CN, Lim SK, Nucleic Acids Res 2010 38 215 224 10.1093/nar/gkp857 19850715
70. Paracrine/endocrine mechanism of stem cells on kidney repair: role of microvesicle-mediated transfer of genetic information. Camussi G, Deregibus MC, Tetta C, Curr Opin Nephrol Hypertens 2010 19 7 12 10.1097/MNH.0b013e328332fb6f 19823086
71. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, Seo BM, Sonoyama W, Zheng JJ, Baker CC, Chen W, Ried T, Shi S, Stem Cells 2006 24 1095 1103 10.1634/stemcells.2005-0403 16282438 (Pubitemid 44464742)
72. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F, PLoS One 2009 4 4992 10.1371/journal.pone.0004992 19352430
73. Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. Psaltis PJ, Paton S, See F, Arthur A, Martin S, Itescu S, Worthley SG, Gronthos S, Zannettino AC, J Cell Physiol 2010 223 530 540 20162565